Inpharmatica Licenses Admensa Interactive™ to Mochida
News Oct 11, 2005
Inpharmatica Ltd has announced that Japanese pharmaceutical company, Mochida, has licensed Admensa Interactive, a suite of predictive drug absorption, distribution, metabolism and excretion models and compound prioritisation tools.
Mochida is the second Japanese company to license Admensa Interactive, Daiichi being the other. This latest customer further endorses the worldwide success of this suite since its launch earlier in the year.
Pharmaceutical companies large and small now use Admensa in the US, Europe and Japan. Under the terms of this new agreement, Mochida will receive a multi-user license to Admensa Interactive.
Admensa Interactive is an integral component of Inpharmatica's gene-to-candidate technology platform, which integrates biology- and chemistry-based drug discovery activities.
This platform optimises target selection based on druggability, and enables rapid identification of hits and selection of high quality leads and pre-clinical candidates, which are prioritised on the basis of good drug-like characteristics and clinical indication.
The agreement was secured in conjunction with PharmaDesign, Inpharmatica's sales and marketing partner in Japan.
John Lisle, CEO of Inpharmatica, said, “Admensa Interactive continues to go from strength to strength, making a valuable contribution to our revenue stream in the very short time since its launch as a product offering. This is our first agreement with Mochida and we are delighted to have them as a customer.”
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Drug Combo Prevents Stroke, Shows Promise for ClinicNews
Taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days following a TIAREAD MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018